suMMARY BRL 26921 is a protected plasminogen-streptokinase complex with selective affinity for thrombus. When given intravenously within three hours of the onset of a first acute myocardial infarction angiographic patency of the infarct related vessel was seen in all 16 patients receiving the active drug compared with only two of 16 receiving a placebo. There was relative sparing of left ventricular function in the active treatment group with anterior infarction (mean left ventricular ejection fraction 37% compared with 23% for placebo), but no significant difference in left ventricular function between the active and placebo groups was seen in patients with inferior infarction.
Myocardial infarction is associated with thrombotic occlusion of a coronary artery in a high proportion of patients during' the first few hours of its onset.1 Clinical studies have shown that reperfusion of previously occluded arteries is possible with thrombolytic agents and have suggested that infarct size may thus be limited.23 Early reperfusion is important as myocardial salvage decreases rapidly, though variably, with time. 4 Thrombolytic agents may be given intravenously or by direct intracoronary infusion. Earlier studies with intravenous streptokinase were difficult to interpret because reperfusion was not assessed angiographically and because many studies allowed entry up to 12 or even 24 hours after infarction. More recent studies with angiographic verification of reperfusion and more restricted entry criteria have shown reperfusion rates of between 600/o and 800/.5 6 Intravenous streptokinase infusion invariably causes systemic fibrinogenolysis and may produce a severe, albeit transient, haemorrhagic diathesis. Intracoronary administration of streptokinase is effective in producing thrombolysis but requires facilities for urgent cardiac catheterisation, which may well limit its applicability outside major cardiac centres. Moreover, Requests for reprints to Dr D P de Bono, Department of Cardiology, The Royal Infirmary, Edinburgh EH3 9YW.
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These disadvantages have led to a search for alternative thrombolytic agents7 and to the development of BRL 26921,8 a complex of streptokinase with anisoylated human plasminogen. The plasminogen selectively binds to fibrin rather than fibrinogen and causes the complex to seek out and bind to thrombus. Plasminogen is normally a potent activator of streptokinase, but to prevent premature activation while the complex is circulating it is temporarily inactivated by coupling an anisoyl group to its active site. This anisoyl group is removed by hydrolysis under in vivo conditions with a half life of approximately 37 minutes. After its removal, the streptokinase is activated and fibrinolysis occurs. In a previous study we showed that BRL 26921 was effective when given by the intracoronary route9; in theory it should be equally effective if given intravenously.
The present study was designed to assess the efficacy and safety of intravenous BRL 26921 in causing coronary reperfusion and myocardial salvage when given within three hours of the onset of myocardial infarction. 254 myocardial infarction, with chest pain of longer than 30 minutes' but less than three hours' duration, had ST elevation of 2 mm or more in at least two electrocardiographic leads, and were able to give informed consent.
Exclusion criteria were age >70 years, systolic blood pressure <90 mm Hg or >200 mm Hg at the time of dosing, previous cerebrovascular accident, active peptic ulcer within one year, any surgery within one month, menstruation, previous treatment with streptokinase, and previous transmural myocardial infarction.
STUDY DESIGN
The primary object of the trial was to determine whether intravenous BRL 26921 was more likely than placebo to produce patent coronary vessels on angiography 90 minutes after drug administration. Although early coronary angiography performed on patients taking a placebo is in our experience both safe and helpful in subsequent management, we felt obliged to answer this question using the smallest practicable number of patients. Been, de Bono, Muir, Boulton, Hillis, Hornung study to an investigator who did not know the number of the vial to be used. We also checked retrospectively for comparability in patients allocated to active and placebo treatments and arranged for the double blind assessment of angiograms as described below.
As soon as possible after admission, a 19 gauge Venflon cannula was placed in a large peripheral vein for blood sampling and drug administration. Baseline samples of blood for measurements of coagulation factors, electrolyte concentration, and enzyme activities, and for blood grouping were taken. BRL 26921 or placebo was freshly reconstituted from freeze dried powder and given as a single intravenous injection.
The initial 5 mg was given over five minutes and the remaining 25 mg over a further 10 minutes. Facilities for dealing with allergic reactions were available but were not in fact used. Blood was drawn for a repeat coagulation test one hour after dosing.
Coronary arteriography Ninety minutes after the start of the BRL 26921 or placebo infusion coronary arteriography was performed in all patients using a procedure room within the coronary care unit, a portable image intensifier, and a videotape recorder. A 7 French gauge sheath was inserted percutaneously in the right femoral artery and arteriography was done by the Judkins's technique using non-ionic contrast medium (Niopam). Heparin was not used. For inferior infarcts the right coronary artery was injected first followed by the left coronary artery. For anterior infarcts the left coronary artery was injected first, followed in most patients by the right. At least two projections of each coronary artery were recorded. Results were classified as occlusions or reperfusions by a single observer who did not know which substance had been given and was not aware of the results of the coagulation test. As an additional safeguard, angiograms were reviewed retrospectively and in random order by an observer blind to patient identity to avoid the possibility of assessment bias from guessing the treatment given. The criteiion for occlusion was an abruptly terminating stump of a major coronary vessel. The criterion for reperfusion was complete filling with contrast of the major coronary vessel in the infarct area within three cardiac cycles; almost invariably there was a severe proximal stenosis.
A prospective decision was made to give anticoagulants to all patients with reperfusion and withhold anticoagulants from all those with persistent coronary occlusion, irrespective of whether they had received BRL 26921 or placebo. The timing of introduction of heparin anticoagulation was based on the results of the one hour coagulation tests, repeated if necessary after four hours. Patients receiving anticoagulation treatment were given heparin by intravenous infusion pump at a rate sufficient to prolong the thrombin time by 50-100%. Heparin was given for five days and followed with oral warfarin anticoagulation. The sheath was removed within 24 hours.
Additional investigations
Coagulation indices-Previous experience with this drug indicated that measurements of coagulation indices one hour after dosing gave values close to those of maximum effect. Fibrinolysis and fibrinogenolysis were assessed by measurement of the euglobulin clot lysis time and plasma fibrinogen concentration. Prothrombin time ratio, thrombin time, partial thromboplastin time, packed cell volume, and platelet count were also measured. Additional information was given by the plasma clotting time with reptilase (the reptilase time),1' which gives a direct measure of the anticoagulant effect of any fibrinogen degradation products on the coagulability of circulating fibrinogen.
Creatine kinase activity-Serial estimations were made of plasma creatine kinase activity at two hourly intervals for 24 hours.
Radionuclide ventniculography-Left ventricular function was assessed in all Edinburgh patients (n=22) by gated blood pool radionuclide ventriculography in the left anterior oblique projection between the eighth and tenth day after admission. The person conducting the test was unaware of the treatment given. Results were analysed separately for anterior and non-anterior infarct groups. Statistical comparison was by an appropriate non-parametric test (Mann Whitney U test). Table 1 shows patient details, treatment received, and angiographic findings. A total of 35 patients were seen who fulfilled the entry criteria and were offered participation in the trial. Three patients declined admission to the study and received standard treatment. Twenty two patients were studied in Edinburgh (10 with anterior and 12 with inferior infarcts) and 10 in Glasgow (four with anterior and six with inferior infarcts). There were equal numbers of patients receiving active treatment and placebo in each centre and in each group. All patients with anterior infarcts were male, and there were two female patients in both
Results
Patients eligible for study (35) Refused consent (3) First transmural myocardial infarction (32) Anterior (14) Inferior (18) Active Placebo Active Placebo treatment (7) treatment (7) treatment (9) treatment (9) Patent left Occlued tent system (7) LAD artery (5) vesse(s (9) Patent (2) Occluded vessels (9) treatment groups with inferior infarcts. The mean age for those receiving active treatment was 58 (10) years (inferior) and 54(8) years (anterior) compared with 52 (11) years (inferior) and 56 (7) years (anterior) for the placebo group. The duration of chest pain before treatment was 2-4 (0.6) hours and 2-6 (0 5) hours for active and placebo groups respectively. There was no significant difference between active and placebo groups in terms of pulse rate, blood pressure, or signs of cardiac failure on admission to the study. Figures 1 and 2 summarise the results.
REPERFUSION
In all patients receiving active treatment the vessel expected to be the cause of the infarction was patent at angiography. All but one of these patients had patency of all three major coronary vessels. Most patients had a severe stenosis in the presumed infarct related vessel, although the degree of stenosis was variable. Additional disease was seen in 50% of the patients, and one had a left main stem stenosis. In the inferior infarct group receiving placebo seven patients had total occlusion of the right coronary artery and two of the left circumflex coronary artery-that is, nine occluded vessels in nine patients. Five of seven patients in the anterior placebo group had total occlusion of a left anterior descending vessel.
In the remaining two patients early spontaneous reperfusion may have occurred.
LEFT VENTRICULAR FUNCTION
Radionuclide ventriculography performed 8 to 10 days after admission showed a variable pattern in the inferior infarct group, with a tendency to better left Been, de Bono, Muir, Boulton, Hillis, Hornung ventricular function in the active treatment group which did not reach statistical significance (ejection fraction 44(5)% active, 40(8)% placebo) ( Table 2) . There was an appreciable difference in the anterior infarct group, with an ejection fraction of 37(7)% in those receiving active treatment compared with 23(5)% in the placebo group (p<O0OS, Table 2 ).
CARDIAC ENZYME ACTIVITY All patients had a significant increase in plasma creatine kinase activity, signifying myocardial damage. The shape of the curve for serial measurements was appreciably different for the active and placebo groups, with a much earlier peak in the active group (Fig. 3) . COAGULATION The difference in effect on left ventricular ejection fraction between anterior and inferior infarction is not unexpected. Anterior infarction is well known to result in a greater reduction in left ventricular function than inferior infarction, and this accords with our finding of better preservation of left ventricular ejection fraction in the active anterior infarct group, while both active and placebo patients in the inferior infarct group had relatively well preserved ventricular function. Although our study group consisted only of patients with a first myocardial infarction the resting ejection fraction at 10 days was rather low in both active and placebo groups compared with the expected mean value of 36% based on the work of Dewhurst and Muir. 13 Our entry criteria may have tended to select patients with more pronounced early electrocardiographic changes, more severe symptoms leading to earlier arrival in hospital, and hence larger potential infarcts.
Although the pattern of creatine kinase release with coronary reperfusion is altered, with a large early peak and rapid decline, the total amount of enzyme released is still thought to correlate with infarct size. 14 In view of the altered shape of the curve in the group with reperfusion we did not feel confident about comparing the area under the curve for the two groups, as extrapolation on from 24 hours may be unreliable.
The numbers in this study are much too small to allow valid data on mortality. Patients who have survived for two or three hours after coronary occlusion are already to some extent "selected" for survival, and we further reduced expected mortality by excluding hypotensive patients. The association of prognosis with ejection fraction does, however, give cause for optimism. ' 3 As yet the best treatment after reperfusion is unclear, and this is likely to influence long term results.
We believe that BRL 26921 is a significant advance in thrombolytic treatment in myocardial infarction. It is potentially widely available and can be given as an intravenous bolus with a high probability that reperfusion will occur within a reasonable time scale. With close attention to exclusion criteria complications can be kept to a minimum. 
